Comment

Australian company Vaxxas has secured close to $90 million in new funding, one of the largest private biotechnology financings in the country this year, as it accelerates development of its needle-free vaccine delivery technology.

Argent BioPharma (ASX:RGT) has announced the results of an independent in vivo study evaluating the efficacy of ArtemiC, the USA OTC Unlicensed Drug Brand name of CimetrA, its lead immunomodulatory therapeutic, in a severe viral inflammatory model targeting Acute Respiratory Distress Syndrome.

Victorian researchers have achieved a world-first breakthrough in brain cancer research, showing how a new drug can suppress tumour activity in patients with low-grade gliomas.

Neuren Pharmaceuticals (ASX:NEU) has announced the initiation of the first investigational site in the US for its Phase 3 clinical trial of NNZ-2591 in Phelan-McDermid syndrome, after receiving Institutional Review Board approval.

Clinical dermatology company, Botanix Pharmaceuticals (ASX:BOT), has announced the appointment of Dr Patricia Walker to its board of directors.

Australia’s life sciences sector is growing rapidly, fuelled by pioneering science and the capital needed to take ideas from research to commercialisation.

CSL reported strong profit growth for the past year, but has launched several strategic initiatives, including separating its vaccine business into a standalone company and reducing the number of plasma collection centres in the US.

LTR Pharma said that the publication provides independent validation of SPONTAN's differentiated profile, showing peak plasma concentrations in approximately 10 minutes versus 45 minutes for conventional oral tablets.

Invion (ASX:IVX) has announced that the US FDA has granted orphan drug designation to INV043 for the treatment of anal cancer.

Neurizon Therapeutics (ASX:NUZ) has reported positive topline results from the Open-Label Extension study of its lead candidate NUZ-001 for the treatment of amyotrophic lateral sclerosis, which is the primary form of motor neurone disease.

Lucia Bio has announced that it has raised an additional $2 million in seed financing, bringing the total seed investment secured to date to $3 million.

Brandon BioCatalyst, a collaboration of more than 50 of Australia and New Zealand’s leading medical research institutes, hospitals and universities, today announced new board appointments.